Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma

Table 2

IL-19 and PD-L1/PD-1 coexpression with CXCR3/CD36 in newly diagnosed lymphoma patients and healthy controls. IQR: interquartile range; pre-T: pretherapy. identifies highly significant differences .

		Controls	Lymphoma patients	value
		Pre-T IL-19 (pg/ml)	Median; IQR		7.2; (4.4-10.9)	237; (86-510.5)	<0.001
Pre-T CXCR3+%	Median; IQR	11.2; (9.7-13.2)	40; (35-65)	<0.001
Pre-T PDL-1+CXCR3+%	Median; IQR	1.1; (1-1.5)	32; (25-54)	<0.001
Pre-T PD-1+CXCR3+%	Median; IQR	0.7; (0.5-1)	10; (8-13)	<0.001
Pre-T CD36+%	Median; IQR	4.2; (3.5-5.7)	13; (12-15)	<0.001
Pre-T CD36+PDL1+%	Median; IQR	1; (0.5-1.4)	8; (6-9)	<0.001
Pre-T PD-1+CD36+%	Median; IQR	0.2; (0.1-0.4)	5; (4-6)	<0.001